On a roll: FormFlow develop two new processes

FormFlow, Deakin University and the Innovative Manufacturing CRC have shared results of a collaborative research partnership, which they say has yielded commercially useful technologies for the metal forming sector. The team originally announced a 12-month project backed by IMCRC’s activate program in January last year, targeting development of a “an Industry 4.0 enabled manufacturing cell”…

Brands are leaning on ‘recycled’ clothes to meet sustainability goals. How are they made? And why is recycling them further so hard?

Recycling clothing isn’t like recycling paper, glass or metal. Clothes are endlessly variable and unpredictable. So they’re not ideal for recycling technologies, which require a steady and consistent source material. Even a seemingly simple garment may contain multiple materials, with fibre blends such as cotton/polyester and cotton/elastane being common.

WA battery metals prospectus targets investment

The Western Australian state government has launched a new prospectus promoting investment opportunities in the state’s growing battery and critical minerals industries. The prospectus, which has already been presented to potential investors in Germany by development minister Roger Cook, aims to build on the state’s minerals endowment and local companies’ increasing involvement in critical metals…

Sparc to manufacture graphene additive coatings

Graphene technology company Sparc Technologies has developed a commercial manufacturing process for the production of graphene based additive products, and will begin manufacture. The company has identified, trailed and ordered specialised graphene based additive manufacturing equipment and has located a manufacturing site. Sparc managing director Mike Bartels said: “Our path to commercialisation is now clear…

BioCina begins trials of Australian-developed Covid-19 vaccine

A second Australian-developed and manufactured Covid-19 vaccine has surfaced with Adelaide company BioCina commencing human trials of a new vaccine that targets the highly-transmissible Omicron variant of the disease. The DNA-based vaccine has been designed by University of Adelaide researchers and is being trialled at Royal Adelaide Hospital in partnership with PARC Clinical Services and…